Correct PRF Centrifuge Speed and Time Protocols

PRF centrifuge protocols vary by the type of product you need, but the field has broadly settled on a range of about 200 to 700 g (relative centrifugal force) for 5 to 8 minutes for most clinical applications, with lower g-forces producing liquid injectable forms and moderate g-forces producing solid membranes and clots. These numbers represent a significant shift from the original high-speed protocols introduced in the early 2000s, and getting them wrong changes what ends up in the fibrin matrix. The details, though, matter more than most practitioners realize, and speed and time are only part of the equation.

Why Relative Centrifugal Force Matters More Than RPM

One of the most persistent sources of confusion in the PRF literature is the habit of reporting centrifugation settings in RPM rather than relative centrifugal force. RPM alone tells you almost nothing about what the blood in the tube actually experiences, because the force depends on both the rotational speed and the radius of the rotor. A tube sitting 10 centimeters from the center of a rotor spinning at 2,700 RPM experiences a very different g-force than the same tube at 6 centimeters. The relationship follows a straightforward formula involving the square of the RPM multiplied by the rotor radius.¹ This means that two clinicians using different centrifuge brands at the same RPM can produce very different PRF products.

A review of the PRF literature found that numerous reports have inaccurately reported RCF values over the years, creating considerable confusion about what protocol was actually used in a given study.² If you are setting up a PRF protocol in your practice, the first step is to find the rotor radius of your specific centrifuge and calculate the actual RCF rather than blindly copying RPM values from a paper or protocol sheet. Most modern PRF-specific centrifuges list this information in the manual, and many have settings that let you enter the desired g-force directly.

The Main Solid PRF Protocols

The original leukocyte- and platelet-rich fibrin protocol, commonly called L-PRF, used what we now consider a relatively high centrifugation speed. Blood was drawn into glass-coated tubes and spun at roughly 400 g for 12 minutes in a fixed-angle centrifuge. The result was a dense fibrin clot with most of the platelets and white blood cells concentrated in a narrow band near the bottom, in the so-called buffy coat region.

Advanced PRF protocols came from research showing that lower centrifugation forces spread cells more evenly throughout the fibrin matrix rather than packing them into a thin layer at the base. In one study examining platelet distribution, the original L-PRF protocol pushed platelets primarily into the lower portion of the matrix, while lower-speed protocols like A-PRF and A-PRF+ produced clots with platelets distributed homogeneously throughout.³ That more even distribution is believed to improve the biological activity of the membrane when placed in a wound or surgical site.

A large evaluation comparing 24 different centrifugation protocols found that the optimal range for solid PRF membranes was between 400 and 700 g for 8 minutes, which produced the greatest yield of evenly distributed cells.⁴ An expert group recommendation based on similar findings suggested using 200 g for 8 minutes (the A-PRF+ protocol) for solid PRF membranes, while a higher-speed option at 700 g for 8 minutes was recommended for concentrated liquid PRF.⁵ The range exists because different clinical situations call for different characteristics in the final product.

Liquid and Injectable PRF Protocols

Injectable PRF, often abbreviated i-PRF, is the liquid fraction collected before the blood has fully clotted. It requires even lower g-forces and shorter spin times than solid PRF, because the goal is to keep the product in a flowable state while still concentrating platelets and leukocytes above baseline levels. The same 24-protocol evaluation found the sweet spot for liquid PRF at 200 to 400 g for 5 minutes, which produced the highest concentration of platelets and leukocytes in the liquid fraction.⁴

Standard i-PRF protocols typically yield a modest increase in platelet concentration compared to whole blood. But a newer approach called concentrated PRF, or C-PRF, flips the logic. Instead of spinning gently and collecting the top layer, C-PRF uses a high-speed protocol and then harvests only the very thin buffy coat layer sitting right above the red blood cell corpuscle. One study used 3,000 g for 8 minutes on a horizontal centrifuge and collected just that narrow layer.⁶ The results were dramatic: while i-PRF increased platelet numbers by roughly 250% over baseline, the C-PRF buffy coat layer showed increases of 1,200 to 1,700%, reaching total platelet concentrations above 2,000–3,000 × 10⁹ cells per liter in just 0.3 to 0.5 mL of harvested material.⁷ The trade-off is volume: you get a tiny amount of highly concentrated material rather than a milliliter or two of moderately enriched liquid.

The Low Speed Centrifugation Concept

The theoretical foundation for reducing centrifugation speeds comes from a concept formally described as the low speed centrifugation concept. The idea is straightforward: during centrifugation, particles migrate based on their size, density, and mass. Red blood cells are heavy and dense, so they move to the bottom readily even at low forces. Platelets and white blood cells are lighter and smaller. At high g-forces, they get dragged down toward the red cell layer and packed tightly into the buffy coat. At lower forces, there is enough separation to pull them away from the red cells but not so much that they aggregate into a narrow band. The result is a wider, more even distribution through the fibrin matrix.⁸

This matters for growth factor release. When platelets and leukocytes are spread throughout the fibrin scaffold, they release their cargo as the fibrin slowly degrades over days. That sustained, gradual release appears to be more biologically useful than a fast dump of growth factors from a thin concentrated layer. A comparison of PRP, traditional PRF, and A-PRF found that while PRP released the most growth factors in the first 15 to 60 minutes, A-PRF released the highest total growth factors over a 10-day period and accumulated significantly more total protein than either PRP or traditional PRF.⁹ A narrative review of the broader literature confirmed this pattern, concluding that lower-speed protocols like A-PRF and i-PRF tend to provide more uniform cell distribution and sustain higher growth factor release over time compared to conventional L-PRF.¹⁰

Horizontal Versus Fixed-Angle Rotors

Speed and time are not the only centrifuge variables that change the product. The type of rotor, specifically whether it holds tubes at a fixed angle or swings them out horizontally during the spin, has a surprisingly large effect on cell distribution and yield. In a fixed-angle centrifuge, the tubes sit at a slant during the entire run. This pushes cells not just downward but also against one wall of the tube, creating an uneven distribution. In a horizontal centrifuge, the tubes swing out perpendicular to the rotor axis, so the force runs straight down the length of the tube.

Histological comparison of PRF clots prepared by the two methods showed that horizontal centrifugation produced much smoother cell layer separation along the tube surfaces and more evenly distributed platelets throughout the clot, while fixed-angle spinning gathered cells along the outer tube wall and in the buffy coat region.¹¹ Quantification of the difference found that horizontal centrifugation produced up to 3.5 times higher numbers and concentrations of both platelets and leukocytes in either solid or liquid PRF compared to fixed-angle devices.¹²

The practical takeaway is that a protocol designed on a horizontal centrifuge will not produce the same product on a fixed-angle machine, even at identical g-force and time. If you are following a published protocol, matching the rotor type matters as much as matching the numbers. Many of the newer optimized protocols, including the C-PRF technique, were developed specifically on horizontal centrifuges.

Vibration and Device-Specific Behavior

Beyond rotor geometry, the mechanical characteristics of the centrifuge itself influence the product. Each centrifuge has its own vibration profile that varies with rotational speed, and those vibrations directly affect the architecture and cell content of the resulting PRF clot. Research found that the original L-PRF clot produced on its designed centrifuge showed very specific structural characteristics that appeared distorted when produced on centrifuges with higher vibration levels.¹³ The same study noted that this variable had never been considered in the broader PRP and PRF literature, meaning that studies comparing protocols may have been confounding centrifugation settings with centrifuge hardware without realizing it.

When comparing mechanical properties of PRF membranes across different devices, tensile strength differences were observed between protocols run on different centrifuges, but no significant difference emerged when the same protocol was run on different machines after adjusting g-force to compensate for hardware differences.¹⁴ This reinforces the idea that if you are switching centrifuge models, recalculating to match the actual RCF rather than the RPM is essential.

Collection Tubes Change the Outcome

The tube that holds the blood during centrifugation is another variable that gets less attention than it deserves. PRF requires coagulation to form, and the surface of the tube is what initiates that process. Glass tubes activate clotting through contact with the silicate in the glass surface, while plastic tubes require a silica coating to achieve the same effect. These two approaches do not produce identical results.

Silica-coated plastic tubes release silica microparticles into the blood, which triggers widespread platelet activation and coagulation throughout the sample. This results in a relatively broad platelet distribution within the PRF matrix regardless of centrifugation speed. Glass tubes, by contrast, activate clotting only at the tube surface, so platelet distribution in glass tubes is speed-dependent, shifting based on the g-force used.¹ This has a practical implication: if you are using silica-coated plastic tubes, the careful speed optimization that distinguishes A-PRF from L-PRF may be partially blunted because the silica particles are doing their own thing to distribute platelets.

A direct comparison confirmed this pattern. Using low-speed centrifugation, platelets were distributed homogeneously within the PRF matrix regardless of tube type. But with high-speed centrifugation, platelets concentrated on one surface of the matrix in glass tubes, while silica-coated tubes produced a more diffuse distribution even at higher speeds.¹⁵ Clot size also differed by tube type, with silica-coated tubes tending to produce heavier clots and glass (Pyrex) tubes producing shorter ones under certain conditions.¹⁶

The Speed of Getting Blood Into the Centrifuge

Here is a variable that many clinicians underestimate: the time between drawing blood and starting the centrifuge. Blood begins clotting the moment it leaves the vein. Since PRF relies on that natural clotting process happening inside the centrifuge (not before it), any delay eats into the available clotting time and reduces the usable product.

One study measured this precisely. A delay of just 90 seconds between the blood draw and the start of centrifugation caused a 13% reduction in PRF membrane size. At 120 seconds, the reduction reached 23%.¹⁷ A follow-up investigation found that immediate centrifugation produced the largest membranes, while a 6-minute delay resulted in membranes that were 29% smaller on average, with significantly fewer leukocytes and platelets. The delayed samples also weakened fibroblast responses in vitro, suggesting the biological activity of the membrane was compromised, not just its size.¹⁸

The practical message is simple: have the centrifuge turned on, programmed, and ready to go before you draw blood. If you are drawing multiple tubes, start loading them into the centrifuge as you go rather than waiting until all tubes are filled. Every minute of delay degrades the product.

Temperature and Heat Treatment

Temperature enters the picture in two ways: the ambient conditions during centrifugation and any intentional heat treatment applied afterward to manipulate the PRF product. Most centrifuges used in clinical PRF preparation do not have temperature controls, so the product spins at whatever ambient temperature the room provides. This is generally fine for standard protocols.

Where temperature becomes relevant is in the newer injectable horizontal PRF (H-PRF) gel protocols, where heat treatment has been explored to alter the consistency of the product. Research shows that as temperature increases, cell death within the gel also increases, though even in heated groups, more than 90% of cells remained viable.¹⁹ However, heating to 90°C or above caused a dramatic reduction of more than two-thirds in cellular activity, essentially destroying the biological benefit of the PRF.²⁰ If you are using heat to modify PRF membrane handling characteristics, staying well below 90°C preserves most of the cellular activity.

What Happens After the Spin

Once the centrifuge stops, the solid PRF clot needs to be processed into a membrane for clinical use. The standard approach is to compress the clot to express excess serum and create a flat, manageable membrane. How you do this turns out to matter. Compressing PRF between dry gauze, a common shortcut, wicks away plasma content along with the serum. Using a dedicated membrane compression device that applies gentle, even pressure without absorbent material preserves the 3D fibrin meshwork, retains more platelets, and keeps higher levels of growth factors like PDGF compared to gauze-compressed membranes. In vitro, the device-compressed membranes stimulated more cell proliferation and new blood vessel formation.²¹

Do Speed Differences Actually Change Clinical Outcomes

The laboratory evidence for low-speed protocols is convincing: more evenly distributed cells, higher sustained growth factor release, larger membranes. But does that translate to better healing? The clinical data so far is more measured. A randomized controlled trial in patients with advanced periodontitis found that low-speed PRF combined with open flap debridement produced significantly greater attachment gain and probing depth reduction than surgery alone at 3, 6, and 9 months.²²

When the question is specifically whether low-speed PRF outperforms traditional high-speed PRF in a living system, the answer is less clear-cut. An animal study comparing L-PRF and A-PRF in critical-size skull defects found that both outperformed controls in bone volume and new bone formation, but there was no significant difference between the two PRF types.²³ A systematic review of platelet concentrates in bone and periodontal regeneration came to a similar conclusion: PRF shows clear adjunctive benefit in certain outcomes and is broadly equivalent to conventional regenerative approaches, but consistent superiority over standard techniques has not been demonstrated across the board.²⁴

The gap between lab-bench improvements and clinical outcomes is common in regenerative medicine. A PRF membrane with twice the growth factors does not necessarily produce twice the bone. The wound environment, patient health, surgical technique, and dozens of other factors all interact with the biology of the membrane. Low-speed protocols appear to produce a better-quality starting material, but whether that difference changes what you see in the patient’s mouth or wound at six months remains an area of active study.

Quick Reference for Common Protocols

Because the naming conventions can get confusing, here is a practical summary of the main protocols and what they produce:

L-PRF (original): Roughly 400 g for 12 minutes in a fixed-angle centrifuge. Produces a solid clot with cells concentrated near the base. The protocol that started the field.
A-PRF / A-PRF+: Roughly 200 g for 8 minutes. Produces a solid clot with cells distributed more evenly. The low-speed approach backed by the most recent optimization data.
i-PRF (injectable): Roughly 200–400 g for 5 minutes. Produces a liquid fraction collected before full clotting. Useful for injections or mixing with bone graft material.
C-PRF (concentrated): High-speed spin (2,000–3,000 g for 8 minutes on a horizontal centrifuge), followed by harvesting only the thin buffy coat layer. Yields a tiny volume with extremely high platelet and leukocyte concentrations.

All of these values are in RCF (g-force), not RPM. Converting to the correct RPM for your centrifuge requires knowing the rotor radius. Using the wrong number means you are running a different protocol than the one you think you are running.

Growth Factor Release Is Not Just About the Clot

An interesting finding that sometimes gets lost in the speed debate is that the type of growth factor release also varies by protocol and by the specific growth factor in question. For instance, a comparison of L-PRF, A-PRF, and titanium-prepared PRF (T-PRF) found that T-PRF released the highest amount of PDGF-AA at early time points, slightly edging out A-PRF. But over time, A-PRF showed a more sustained release profile.²⁵ The clinical implication depends on what you are trying to achieve. If you need an early burst of growth factors to kickstart cell migration, a different protocol might be preferred than if you want steady delivery over a week of healing.

The broader optimization research, including the development of C-PRF protocols, suggests that centrifugation at 700 RCF for 8 minutes was best able to evenly distribute cells in the upper plasma layer for solid membranes, while 200–300 RCF for 5 minutes represented a more optimized injectable protocol. The concentrated approach at 2,000 RCF for 8 minutes represented something new entirely, achieving roughly a 10-fold increase in baseline platelet and white blood cell concentrations in the harvested buffy coat layer.²⁶ Each of these represents a distinct clinical tool rather than an incremental improvement on the same idea.